Long-term Safety of Subjects Continuing Dolutegravir After Participation in Clinical Studies of Dolutegravir in Russian Federation
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Jun 2018
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors ViiV Healthcare
- 05 Jun 2018 Planned End Date changed from 31 Jul 2018 to 14 Sep 2018.
- 05 Jun 2018 Planned primary completion date changed from 31 Jul 2018 to 14 Sep 2018.
- 01 Mar 2018 Status changed from recruiting to active, no longer recruiting.